Towa Pharmaceutical announced the personnel changes at the General Meeting of Shareholders and Board of Directors held on June 24, 2026, revealing new and reappointed directors. President and CEO Ichiro Yoshida will continue in his role, while Koji Nakamura was newly appointed as a director.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-06-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4553-20260624-01.pdf","jir_short_summary":"Towa Pharmaceutical announced the personnel changes at the General Meeting of Shareholders and Board of Directors held on June 24, 2026, revealing new and reappointed directors. President and CEO Ichiro Yoshida will continue in his role, while Koji Nakamura was newly appointed as a director.","jir_summary":"### Overview of Executive Changes\nTowa Pharmaceutical resolved upon its executive personnel changes at the Shareholders\u2019 Meeting and Board of Directors held on June 24, 2026. President and CEO Ichiro Yoshida will continue serving, and Koji Nakamura, who is also the Head of the President\u2019s Office and in charge of the Management Strategy Division, was newly appointed as a director. Other executives were also reappointed, resulting in a stable leadership structure.\n\n### Impact of the Executive Changes and Future Outlook\nThe recent executive personnel changes aim to maintain and stabilize the company's management structure, which is expected to play an important role in advancing future business strategies. In particular, the appointment of Koji Nakamura as the person responsible for management strategy is anticipated to contribute to future business development and the promotion of new businesses. The appointment also includes responsible executives, strengthening the accountability system in accordance with the Pharmaceuticals and Medical Devices Act.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #ExecutiveChange, #JapaneseStocks","jir_key_figures":"Management structure: President and CEO Ichiro Yoshida, reappointment and new appointment of other executives\nNewly appointed director: Koji Nakamura (Director, Head of the President\u2019s Office and in charge of the Management Strategy Division)\nDate of executive decision: June 24, 2026","jir_meta_title":"\u3010Towa Pharmaceutical\u3011Announcement of Executive Changes | June 24, 2026","jir_meta_description":"Towa Pharmaceutical resolved upon its executive personnel changes on June 24, 2026, announcing new and reappointed directors. The President and CEO remains in office to ensure management stability.","jir_og_title":"\u3010Towa Pharmaceutical\u3011Announcement of Executive Changes | June 24, 2026","jir_og_description":"Towa Pharmaceutical has approved executive personnel changes, announcing appointments of new directors and the continuation of the current management team, contributing to future strategic planning.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-68437","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n